Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 237

The DOI matches its Crossref record.

Management of Antiviral Resistance in Patients with Chronic Hepatitis B

Open access
Locarnini, Stephen, Hatzakis, Angelos, Heathcote, Jenny, Keeffe, Emmet B, Liang, T Jake, Mutimer, David, Pawlotsky, Jean-Michel, Zoulim, Fabien·2004·Antiviral Therapy

Abstract

A meeting of physicians and scientists involved in the management of chronic hepatitis B (CHB) was held to review current scientific data regarding antiviral resistance in hepatitis B virus (HBV) infection. The goals of the meeting were to describe current treatments for CHB, discuss emerging issues in HBV drug resistance and to delineate patient monitoring, including markers for resistance, during administration of antiviral therapy. The aim of this review article is to provide treating physicians with a framework for the management of CHB in the context of antiviral resistance. Definitions of primary and secondary antiviral treatment failure can be used to aid monitoring and early diagnosis of drug resistance before disease progression occurs as a consequence of viral breakthrough. Primary antiviral treatment failure is defined as failure of a drug to reduce HBV DNA levels by ≥1xlog 10 IU/ml within 3 months following initiation of therapy, and secondary antiviral treatment failure as a rebound of HBV replication of ≥1xlog 10 IU/ml from nadir in patients with an initial antiviral treatment effect (≥1xlog 10 IU/ml decrease in serum HBV DNA). Confirmation of antiviral drug failure can be established by sequencing the HBV DNA polymerase and identifying specific genetic markers of antiviral drug resistance. In addition to virological assays, HBV resistance can be assessed from a clinical perspective including increased serum alanine aminotransferase levels and the development of systemic symptoms or signs of liver failure. Potential strategies to prevent the emergence of resistance and how to manage drug-resistant HBV once it emerges are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/135965350400900522

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 237

Metadata

Authors
Locarnini, S., Hatzakis, A., Heathcote, J., Keeffe, E. B., Liang, T. J., Mutimer, D., Pawlotsky, J.-M., & Zoulim, F.
Venue
Antiviral Therapy
Published
2004-07
Volume
9
Issue
5
Pages
679-693
ISSN
  • 1359-6535 (ISSN-L)
  • 2040-2058
OpenAlex
W133318803
Cited by
237
References
0
FWCI
18.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of Antiviral Resistance in Patients with Chronic Hepatitis B. https://app.cochat.ai/papers/10.1177/135965350400900522
The paper
Locarnini, S., Hatzakis, A., Heathcote, J., Keeffe, E. B., Liang, T. J., Mutimer, D., Pawlotsky, J.-M., & Zoulim, F. (2004). Management of Antiviral Resistance in Patients with Chronic Hepatitis B. Antiviral Therapy. https://doi.org/10.1177/135965350400900522

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.